Medicines & Healthcare products Regulatory Agency

MHRA Regulating Medicines and Medical Devices

Public Assessment Report

UKPAR

Ibuprofen 600mg Effervescent Granules

(Ibuprofen)

UK Licence No: PL 00037/0678

Abbott Laboratories Limited.

LAY SUMMARY

Ibuprofen 600mg Effervescent Granules
(ibuprofen)

This is a summary of the Public Assessment Report (PAR) for Ibuprofen 600mg Effervescent Granules (PL 00037/0678). It explains how Ibuprofen 600mg Effervescent Granules was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Ibuprofen 600mg Effervescent Granules.

For practical information about using Ibuprofen 600mg Effervescent Granules patients should read the package leaflet or contact their doctor or pharmacist.

What are Ibuprofen 600mg Effervescent Granules and what are they used for?
This medicine is used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), arthritis of the spine (ankylosing spondylitis), swollen joints, frozen shoulder, bursitis, tendinitis, tenosynovitis, lower back pain, sprains and strains.

Ibuprofen 600 mg Effervescent Granules can also be used to treat other painful conditions such as toothache, pain after operations, period pain and headache, including migraine.

This application is the same as Brufen Granules (PL 46302/0007) which is already authorised.

The company (Mylan Products Ltd) that makes Brufen Granules (PL 46302/0007) has agreed that its scientific data can be used as a basis for the grant of an identical licence for Ibuprofen 600 mg effervescent Granules.

How do Ibuprofen 600mg Effervescent Granules work?
This medicine contains the active ingredient ibuprofen which belongs to a group of medicines called anti-inflammatory pain killers which relieve pain, reduce swelling and lower temperature when the patient has a fever.

How are Ibuprofen 600mg Effervescent Granules used?
The pharmaceutical form of this medicine is an effervescent granule and the route of administration is oral (by mouth).

The patient should always take Ibuprofen 600 mg Effervescent Granules exactly as their doctor has told them. If they are not sure, the patient should refer to the label on the carton or check with their doctor or pharmacist.

The granules should be taken by emptying the contents of the sachet into a glass full of water to make an orange flavoured fizzy drink, stir and drink immediately. Take with or after food.

DOSAGE:
Adults and Children over 12 years - The usual dosage is 1 sachet taken two or three times a day. The patient's doctor may choose to increase or decrease this depending on what the patient is being treated for, but no more than 4 sachets should be taken in one day.

Ibuprofen 600 mg Effervescent Granules are NOT recommended for children under 12 years of age.

The patient should avoid excessive use of painkillers. If the patient usually takes painkillers, especially combinations of different painkillers, they may damage their kidneys, the patient should tell their doctor if they are already taking another painkiller before taking this medicine so their doctor can decide whether they should take this medicine. This risk may be increased if the patient is dehydrated.

If the patient has taken more ibuprofen than they should, or if children have taken this medicine by accident always contact a doctor or nearest hospital to get an opinion of the risk and advice on action to be taken.

The symptoms can include nausea, stomach pain, vomiting (may be blood streaked), headache, ringing in the ears, confusion and shaky eye movement.

At high doses, drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness and dizziness, blood in urine, cold body feeling, and breathing problems have been reported.

This medicine can only be obtained with a prescription.

For further information on how Ibuprofen 600mg Effervescent Granules are used, refer to the package leaflet and Summary of Product Characteristics available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

What benefits of Ibuprofen 600mg Effervescent Granules have been shown in studies?
This medicine is considered identical to previously authorised Brufen Granules (PL 46302/0007) with the same benefits and risks. So, no new studies have been provided for Ibuprofen 600mg Effervescent Granules, but reference is made to the studies for Brufen Granules (PL 46302/0007).

What are the possible side effects from Ibuprofen 600mg Effervescent Granules?
Like all medicines, this medicine can cause side effects, although not everybody gets them.

Ibuprofen 600mg Effervescent Granules is considered to be identical to the previously authorised application for Brufen Granules (PL 46302/0007) with the same benefits and risks.

For a full list of all the side effects reported with Ibuprofen 600mg Effervescent Granules see section 4 of the package leaflet, available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

For the full list of restrictions, see the package leaflet.

Why was Ibuprofen 600mg Effervescent Granules approved?
The MHRA decided that the benefits of Ibuprofen 600mg Effervescent Granules are greater than the risks and recommended that they are approved for use.

What measures are being taken to ensure the safe and effective use of Ibuprofen 600mg Effervescent Granules?
A Risk Management Plan has been developed to ensure that Ibuprofen 600mg Effervescent Granules are used as safely as possible. Based on this plan, safety information has been included in the Summary of Product Characteristics and the package leaflet for Ibuprofen 600mg Effervescent Granules including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously.

Other information about Ibuprofen 600mg Effervescent Granules

A Marketing Authorisation was granted in the UK, on 20 July 2018.

The full PAR for Ibuprofen 600mg Effervescent Granules follows this summary.

For more information about treatment with Ibuprofen 600mg Effervescent Granules read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in August 2018.

TABLE OF CONTENTS

I INTRODUCTION

The Medicines and Healthcare products Regulatory Agency (MHRA) granted Abbott Laboratories Limited a Marketing Authorisation for the medicinal product Ibuprofen 600mg Effervescent Granules (PL 00037/0678) on 20 July 2018.

This product is a prescription only medicine (POM).

Ibuprofen 600mg Effervescent Granules are indicated for their analgesic and anti- inflammatory effects in the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies.

In the treatment of non-articular rheumatic conditions, Ibuprofen 600mg Effervescent Granules are indicated in peri-articular conditions such as frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis and low back pain; Ibuprofen can also be used in soft-tissue injuries such as sprains and strains.

Ibuprofen 600mg Effervescent Granules are also indicated for their analgesic effect in the relief of mild to moderate pain such as dysmenorrhoea, dental and post-operative pain and for symptomatic relief of headache including migraine headache.

This application was submitted as a simple abridged (informed consent) application according to Article 10c of Directive 2001/83/EC, as amended.

The application cross-refers to the medicinal product Brufen Granules which was first authorised to the marketing authorisation holder (MAH) Knoll Pharma Limited (PL 13530/0003) on 01 April 1993 and subsequently underwent several changes of ownership procedures of which the most recent was to the current MAH, Mylan Products Ltd, on 07 September 2016 (PL 46302/0007).

Ibuprofen is a propionic acid derivative with analgesic, anti-inflammatory and anti- pyretic activity. The drug's therapeutic effects as a non-steroidal anti-inflammatory drug (NSAID) is thought to result from its inhibitory effect on the enzyme cyclo-oxygenase, which results in a marked reduction in prostaglandin synthesis.

No new data were submitted nor were necessary to be submitted for this application, as the data are identical to the data for the previously granted cross-referenced product.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product type at all sites responsible for the manufacture and assembly of this product.

II QUALITY ASPECTS

II.1 Introduction

This is an abridged application for Ibuprofen 600mg Effervescent Granules (PL 00037/0678) submitted under Article 10c of Directive 2001/83/EC, as amended.

The application cross-refers to the medicinal product Brufen Granules which was first authorised to the marketing authorisation holder (MAH) Knoll Pharma Limited (PL 13530/0003) on 01 April 1993 and subsequently underwent several changes of ownership procedures of which the most recent was to the current MAH, Mylan Products Ltd, on 07 September 2016 (PL 46302/0007). The application is considered valid.

II.2. Drug Substance

Drug substance specification

The proposed drug substance specification is consistent with the details registered for the cross-reference product.

II.3. Medicinal Product

Name

The proposed product name for this application is Ibuprofen 600mg Effervescent Granules. The product has been named in line with current requirements.

Strength, pharmaceutical form, route of administration, container and pack sizes

Each sachet contains 600 mg ibuprofen. The finished product is packaged into a heat-sealed sachet consisting of a paper/polythene/aluminium foil/polythene laminate and is available in pack sizes of 2, 3, 20, 21, 50 and 100 sachets.

The proposed shelf life of the unopened product is 3 years with the storage conditions ‘Store below 25°C.’

The proposed packaging, shelf-life and storage conditions are consistent with the details registered for the cross-reference product.

Legal status

Prescription only medicine (POM).

Marketing Authorisation Holder/Contact Persons/Company

Abbott Laboratories Limited, Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK

The Qualified Person (QP) responsible for pharmacovigilance is stated and a satisfactory CV has been provided.

Manufacturers

The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

Qualitative and quantitative composition

The proposed composition is consistent with the details registered for the cross-reference product.

Manufacturing process
The proposed manufacturing processes are consistent with the details registered for the cross-reference product and the maximum batch size is stated.

Finished product/shelf-life specification
The proposed finished product specification is in line with the details registered for the cross-reference products.

TSE Compliance
None of the excipients used contain material of animal or human origin.

Bioequivalence
No bioequivalence data are required to support this simple abridged application because the proposed product is manufactured to the same formula utilising the same processes as the cross-reference product, Brufen Granules (PL 46302/0007).

Expert Report
The applicant cross-refers to the data for Brufen Granules (PL 46302/0007) to which this application is claimed to be identical. This is acceptable.

Product Name and Appearance
See Section II.3 ‘Medicinal Product; Name’ for details of the proposed product name. The appearance of the product is identical to that of the cross-reference product.

II.4 Discussion on chemical, pharmaceutical and biological aspects

The data submitted with this application is acceptable. The grant of a Marketing Authorisation is recommended.

III NON-CLINICAL ASPECTS

Introduction

As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new non-clinical data have been supplied and none are required.

Ecotoxicity/environmental risk assessment (ERA)

Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As the application is an identical version of an already authorised product, it is not expected that environmental exposure will increase following approval of the Marketing Authorisation for the proposed product.

Discussion on the non-clinical aspects

The grant of a Marketing Authorisation is recommended.

IV CLINICAL ASPECTS

Introduction

As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new clinical data have been supplied and none are required.

Risk Management Plan (RMP)

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended.

There are no differences from the reference product in terms of proposed uses, maximum pack size / strength or pharmaceutical form / formulation that would have any implications for safety.
In line with the reference product, the applicant proposes only routine pharmacovigilance and routine risk minimisation measures for all safety concerns (labelling in the SmPC and the PIL). This is agreed and the RMP is approved.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation.
The MAH is reminded that an updated RMP should be submitted, whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile.

Discussion on the clinical aspects

The grant of a Marketing Authorisation is recommended.

V User consultation

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to the PIL for Brufen Granules (PL 46302/0007). The bridging report submitted by the applicant is acceptable.

VI Overall conclusion, benefit/risk assessment and recommendation

The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The applicant's product is identical to the cross-reference product. Extensive clinical experience with ibuprofen is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is, therefore, considered to be positive.

Summaries of Product Characteristics (SmPC), Patient Information Leaflets (PIL) and Labels

The SmPC and PIL are consistent with the details registered for the cross-reference product.

In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website.

The approved labelling for this medicine is presented below:


Ibuprofen
600mg Effervescent Granules
Ibuprofen 600mg
20 Sachets
MA holder:
Abbott Laboratories Ltd.,
Abbott House, Vanwall Business Park,
Vanwall Road, Maidenhead, Berkshire,
SL6 4XE, UK.
PL 00037/0678
Abbott
8 002660 024628
POM
Each sachet contains 600mg Ibuprofen.
Contains sucrose and sodium.
Sodium content: 150mg per sachet.
Oral use as directed by the doctor.
Read the package leaflet before use.
Empty the contents of the sachet into a glass of water, stir and drink immediately.
Check that each sachet is intact before use.
Keep out of the sight and reach of children.
Store below 25°C.
See leaflet for further information.
Ibuprofen
600mg Effervescent Granules
Ibuprofen 600mg
20 Sachets
LOT
EXP
20010527


23,3
CUT-OFF - PASSO 120 mm.
8,5
2,5
REEL-WIDTH - FASCIA 56,5 mm.
10,7
11
1,5
4
26,32
20010536
POM
Ibuprofen
600mg Effervescent Granules
Ibuprofen 600mg
Each sachet contains 600mg Ibuprofen.
Contains sucrose and sodium.
Sodium content: 197mg/sachet
Oral use as directed by the doctor.
Read the package leaflet before use.
Empty the contents of the sachet into a glass of water, stir and drink immediately.
Check that each sachet is intact before use.
Keep out of the reach and sight of children
Store below 25°C.
See leaflet for further information.
Abbott
MA holder:
Abbott Laboratories Ltd., Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK. PL 00037/0678
EXP
LOT

Annex 1

Table of content of the PAR update

Steps taken after the initial procedure with an influence on the Public Assessment Report (Type II variations, PSURs, commitments)

Scope	**Procedure number**	**Product information affected**	**Date of start of the procedure**	**Date of end of procedure**	**Approval/ non approval**	**Assessment report attached Y/N (version)**